CD202b / TEK pTyr992 antibody Ab
- Known as:
- CD202b / TEK pTyr992 (anti-) Antibody
- Catalog number:
- 1488172
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- Acris antibodies
- Gene target:
- CD202b / TEK pTyr992 antibody
Related genes to: CD202b / TEK pTyr992 antibody Ab
- Gene:
- TEK NIH gene
- Name:
- TEK receptor tyrosine kinase
- Previous symbol:
- VMCM
- Synonyms:
- TIE2, TIE-2, VMCM1, CD202b
- Chromosome:
- 9p21.2
- Locus Type:
- gene with protein product
- Date approved:
- 1994-05-24
- Date modifiied:
- 2018-08-07
Related products to: CD202b / TEK pTyr992 antibody Ab
Related articles to: CD202b / TEK pTyr992 antibody Ab
- Little is known regarding the extent to which the barriers separating brain subcompartments lead to differential drug transport into these subcompartments and whether such differences impact the behavioral effects of drugs. Against this background, here we have adopted electrochemical aptamer-based (EAB) sensors, a seconds-resolved, in vivo molecular measurement tool, to two tasks. First, we have measured the pharmacokinetics associated with the anesthetic procaine crossing the blood-brain-barrier into the solid tissue of the hippocampus and crossing the blood-cerebrospinal fluid barrier into the lateral ventricle. Second, we have determined the extent to which procaine concentrations in these two subcompartments correlate with the behavioral response the drug elicits. Performing these studies, we find that, whereas the drug's elimination kinetics are effectively indistinguishable between the two subcompartments, penetration into the hippocampus is statistically significantly slower than into the lateral ventricle. The relationships between drug concentration and the resulting behavioral effect also differ significantly between the two subcompartments, with the correlation between concentration and drug-induced suppression of ambulatory behavior being stronger in the hippocampus than in the lateral ventricle. This difference presumably arises because hippocampal concentrations more accurately reflect procaine exposure at the drug's site of action. - Source: PubMed
Publication date: 2026/07/07
Honeywell Kevin MGerson JulianErdal Murat KMcDonough Matthew HStocco Marlaina RLeung Kaylyn KEmmons Nicole AGibson Jenny MBui Kirstin NMeiring WendyHespanha João PPlaxco Kevin WKippin Tod E - Fournier's gangrene (FG) is a rapidly progressive, life-threatening necrotizing fasciitis of the perineal and genital region. Despite advances in surgical and medical management, morbidity remains high. Early identification of disease severity and prognosis is essential for timely intervention. This study aimed to evaluate the prognostic value of routinely available inflammatory and metabolic markers-particularly C-reactive protein (CRP) and white blood cell (WBC) count-and to establish clinically applicable admission cut-off values for predicting clinical outcomes, including prolonged hospitalization and surgical burden. - Source: PubMed
Böcü KadirUğur Doğucan NuriAltınkaya Nurullah - This study aimed to evaluate the diagnostic approaches, treatment modalities, and clinical outcomes of patients presenting to the emergency department following razor blade ingestion. - Source: PubMed
Bayraktar Yahya AlperenGemici Kazım - Sporadic venous malformations are a prevalent vascular anomaly in the oral and maxillofacial region. Current therapeutic strategies are associated with high recurrence rates and limited applicability in critical anatomical regions. Therefore, there is a pressing demand for more effective treatment modalities to address these challenges. - Source: PubMed
Li YiHe YangLin JianWang TongWang WeiTang Zhencun - The phosphoinositide 3-kinase alpha inhibitor alpelisib has been increasingly used in the treatment of venous malformations. In this systematic review of 47 patients with a molecular diagnosis for their venous malformations treated with alpelisib, a partial or complete radiological response was achieved by 77% of evaluable patients and symptomatic improvement in 98%. Adverse effects were predominantly mild, with hyperglycaemia the most frequent, occurring in 58% of patients with available safety data. TRIAL REGISTRATION: PROSPERO Registration: CRD420261339549. - Source: PubMed
Publication date: 2026/07/05
Phan JulieTran ChristopherSrinivasa ShwetaSebaratnam Deshan F